2月6日，立春刚过，医药圈的空气里就闻到了一丝火药味。成都倍特药业的3类仿制药——盐酸艾司氯胺酮注射液获批上市，并视同通过一致性评价。截图来源：NMPA官网这不仅仅是一张批件，更是一声发令枪。在艾司氯胺酮注射液这个细分战场，恒瑞医药利用先发优势（首家上市）和强大的麻醉渠道销售能力，构建了近乎垄断的地位。对于新入局者成都倍特而言，这既是坏消息也是好消息——坏消息是对手太强，好消息是市场还没有被充分...
Source Link2月6日，立春刚过，医药圈的空气里就闻到了一丝火药味。成都倍特药业的3类仿制药——盐酸艾司氯胺酮注射液获批上市，并视同通过一致性评价。截图来源：NMPA官网这不仅仅是一张批件，更是一声发令枪。在艾司氯胺酮注射液这个细分战场，恒瑞医药利用先发优势（首家上市）和强大的麻醉渠道销售能力，构建了近乎垄断的地位。对于新入局者成都倍特而言，这既是坏消息也是好消息——坏消息是对手太强，好消息是市场还没有被充分...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.